Health Blueprint

Back to Longevity News

News summary

Why do some patients respond to drugs and others don't? Switchpoint Bio raises $5.3M to find out

Source: Tech.eu • Published: 11 Nov 2026, 09:48

Summarized by Masters of Longevity from Tech.eu.

Startup will use targeted DNA methylation and AI to track drug response from blood.

Why do some patients respond to drugs and others don't? Switchpoint Bio raises $5.3M to find out
Key Takeaways
  • Targeted DNA methylation from blood is being developed to reveal biology.
  • AI-enhanced epigenomic profiling may provide earlier mechanistic readouts.
  • Clinical testing in lupus has not established causal treatment efficacy.
Read the full article at Tech.eu ↗

Continue exploring

Recommended MoL Picks

MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.